Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia
NCT ID: NCT00455026
Last Updated: 2013-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2006-03-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EEG-based Depth of Anesthesia-monitoring, Effects on Dosage and Cognition
NCT04529304
A Phase IV Study Investigating the Effects of Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes
NCT02287181
Remifentanil Effect on Burst Suppression Ratio
NCT06237101
Predicting Bispectral Index Values by Estimated Effect-site Concentration of Propofol and Remifentanil Displayed on the Target-centered Infusion Pump
NCT01604226
Dreaming During Anaesthesia and Anaesthetic Depth
NCT00226876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
0 ng/ml target effect site concentration remifentanil
remifentanil
target effect site concentration during induction
2
2 ng/ml target concentration remifentanil
remifentanil
target effect site concentration during induction
3
4 ng/ml target effect site concentration remifentanil
remifentanil
target effect site concentration during induction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
remifentanil
target effect site concentration during induction
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Epilepsy or other EEG abnormality
* Prescription or illicit drugs known to affect the EEG
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biopharmica Limited
INDUSTRY
Melbourne Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cortical Dynamics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kate Leslie, MD
Role: PRINCIPAL_INVESTIGATOR
Melbourne Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swinburne University
Hawthorn, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005.236
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.